Biochemical and Histopathological Evaluation of The Effect of Thiamine Pyrophosphate on Favipiravir-İnduced Degenerative Corneal and Scleral Damage in Rats

Research Article




Favipiravir, Ocular Toxicity, Oxidative Stress, Thiamine Pyrophosphate


Introduction: Favipiravir causes ocular toxicity at high doses. Thiamine pyrophosphate (TPP) therapy can prevent ocular damage by reversing oxidative damage.

Objective: To investigate the ocular effect of favipiravir in rats and determine the protective effect of thiamine pyrophosphate (TPP) against the possible ocular toxicity of favipiravir.

Method: The rats were randomly divided into three groups; healthy control (HC), favipiravir administered (FAV), and TPP + favipiravir administered (TFAV). In the TFAV group, TPP was intraperitoneally injected at a dose of 25 mg/kg. In the HC and FAV groups, distilled water was applied as a solvent. One hour later, favipiravir was administered to the FAV and TFAV groups at 200 mg/kg orally by gavage twice a day. TPP was injected once a day. This procedure was repeated for one week. All rats were sacrificed under anesthesia, and the biochemical parameters and histopathological levels were analyzed.

Results: It was determined that the FAV group had higher blood MDA levels (p<0.001) and lower tGSH, SOD, and CAT levels (p<0.001) than the other groups. MDA levels of HC and TFAV groups were similar (p=0.407). It also inhibited the reduction in TPP, tGSH, SOD, and CAT (p<0.001). There was no significant difference between HC and TFAV groups regarding tGSH and CAT (p>0.05). In the histopathological examinations, severe collagen fiber degeneration and moderate hyperemia were observed in the corneal and scleral tissues in the FAV group.

Conclusion: The findings of the study showed that favipiravir caused damage to the cornea and sclera tissue through oxidative damage and TPP reduced this damage. Our study results suggest that TPP may be beneficial in Favipiravir-induced ocular toxicity.

Keywords: Favipiravir, Ocular Toxicity, Oxidative Stress, Thiamine Pyrophosphate.


Łagocka R, Dziedziejko V, Kłos P, Pawlik A. Favipiravir in therapy of viral infections. Journal of Clinical Medicine. 2021;10(2):273.

Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research. 2013;100(2):446-54.

McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infectious Diseases. 2020;7(4):ofaa105.

Hashemian SM, Farhadi T, Velayati AA. A review on favipiravir: the properties, function, and usefulness to treat COVID-19. Expert Review of Anti-infective Therapy. 2021;19(8):1029-1037.

Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Research 2018;153:85-94.

Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & Therapeutics. 2020;209:107512.

Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. New England Journal of Medicine. 2020;383(19):1813-1826.

Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? Journal of Virus Eradication. 2020;6(2):45-51.

Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: A prospective, multicenter, open-label, randomized controlled clinical trial. Frontiers of Pharmacology. 2021;12:683296.

Doğan E, Çeviker S, Vurucu S, et al. Investigation of the frequency of adverse effects in patients treated with favipiravir as SARS-CoV-2 treatment. Klimik Journal. 2021:34(2):95-98.

Doran MA, Aytogan H, Ayıntap E. Fluorescence of ocular surface in a Covid -19 patient after favipiravir treatment: a case report. Virology Journal. 2021;18(1):146.

Kara A, Yakut S, Caglayan C, Atçalı T, Ulucan A, Kandemir FM. Evaluation of the toxicological effects of favipiravir (T-705) on liver and kidney in rats: biochemical and histopathological approach. Drug and Chemical Toxicology. 2023;46(3):546-556.

Gangolf M, Czerniecki J, Radermecker M, et al. Thiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cells. Plos One. 2010;5(10):e13616.

Cinici E, Cetin N, Ahiskali I, et al. The effect of thiamine pyrophosphate on ethambutol-induced ocular toxicity. Cutaneous and Ocular Toxicology. 2016;35(3):222-227.

Cinici E, Ahiskali I, Cetin N, et al. Effect of thiamine pyrophosphate on retinopathy induced by hyperglycemia in rats: A biochemical and pathological evaluation. Indian Journal of Ophthalmology. 2016;64(6):434-439.

Góth L. A simple method for determination of serum catalase activity and revision of reference range. Clinica Chimica Acta. 1991;196(2-3):143-151.

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry. 1976;72:248-254.

Zi Y, Deng Y, Zhao J, et al. Morphologic and biochemical changes in the retina and sclera induced by form deprivation high myopia in guinea pigs. BMC Ophthalmology. 2020;20(1):105.

Suresh PK, Sah AK, Daharwal SJ. Role of free radicals in ocular diseases: An overview. Research Journal of Pharmacy and Technology. 2014;7(11):1330-1344.

Nita M, Grzybowski A. The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxidative Medicine and Cellular Longevity. 2016;2016:3164734.

Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Medicine and Longevity. 2014;2014:360438.

Sunar M, Yazici GN, Mammadov R, Kurt N, Arslan YK, Süleyman H. Coenzyme Q10 effect on cisplatin-induced oxidative retinal injury in rats. Cutaneous and Ocular Toxicology. 2021;40(4):312-318.

Karakurt Y, Süleyman H, Keskin Cimen F, et al. The effects of lutein on optic nerve injury induced by ethambutol and isoniazid: an experimental study. Cutaneous and Ocular Toxicology. 2019;38(2):136-140.

Icel E, Uçak T, Agcayazi B, et al. Effects of Pycnogenol on cisplatin-induced optic nerve injury: an experimental study. Cutaneous and Ocular Toxicology. 2018;37(4):396-400.

Goc Z, Szaroma W, Kapusta E, Dziubek K. Protective effects of melatonin on the activity of SOD, CAT, GSH-Px and GSH content in organs of mice after administration of SNP. The Chinese Journal of Physiology. 2017;60 (1):1-10.

Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Molecular Aspects of Medicine. 2009;30(1-2):1-12.

Kurutas EB. The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state. Nutrition Journal. 2016;15(1):71.

Ighodaro O, Akinloye O. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alexandria Journal of Medicine. 2018;54(4):287-293.

Yazici GN, Sunar M, Süleyman B, Abdülkadir Çoban T, Kemal Arslan Y, Süleyman H. Effect of pycnogenol on ethanol-related oxidative retinal injury: an experimental study. European Review for Medical and Pharmacological Sciences. 2022;26(14):5225-5232.

Desco MC, Asensi M, Márquez R, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes. 2002;51(4):1118-1124.




How to Cite

Bayrakçeken, K., Akgöz, H., Ağgül, A. G., Altındağ, F., & Süleyman, H. (2023). Biochemical and Histopathological Evaluation of The Effect of Thiamine Pyrophosphate on Favipiravir-İnduced Degenerative Corneal and Scleral Damage in Rats : Research Article. Acta Medica Ruha, 1(3), 228–238.



Research Articles